Pneumocystis jirovecii pneumonia in kidney transplantation

Transplant Infectious Disease

Volumn 13, Issue 6, 2011, Pages 551-558

  Goto, N ^a   Oka, S ^b  

^a NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Diagnosis; Isolation; Kidney transplantation; Non HIV; PCP; Pneumocystis jirovecii pneumonia; Prophylaxis; Treatment

Indexed keywords

ATOVAQUONE; CALCINEURIN INHIBITOR; CLINDAMYCIN; COTRIMOXAZOLE; CREATININE; CYCLOSPORIN; DAPSONE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; PREDNISONE; PRIMAQUINE; RAPAMYCIN; TACROLIMUS; TRIMETHOPRIM;

BONE MARROW SUPPRESSION; CREATININE BLOOD LEVEL; DISEASE TRANSMISSION; DRUG EFFICACY; ENVIRONMENTAL EXPOSURE; EPIDEMIC; FUNGUS ISOLATION; GASTROINTESTINAL SYMPTOM; GRAFT DYSFUNCTION; HEMOLYTIC ANEMIA; HEPATITIS; HOSPITAL INFECTION; HUMAN; HYPERKALEMIA; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; INFECTION SENSITIVITY; KIDNEY TRANSPLANTATION; MEDICAL SOCIETY; MORBIDITY; MORTALITY; NONHUMAN; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; RECIPIENT; RISK FACTOR; SHORT SURVEY; SIDE EFFECT;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CROSS INFECTION; HUMANS; IMMUNOCOMPROMISED HOST; KIDNEY TRANSPLANTATION; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; POSTOPERATIVE COMPLICATIONS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84155180920     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2011.00691.x     Document Type: Short Survey

References (68)

1. Stansell JD, Osmond DH, Charlebois E, et al. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997; 155 (1): 60-66.
2. Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002; 137 (5 Pt 2): 435-478.
3. Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992; 267 (6): 832-837.
4. Limper AH, Offord KP, Smith TF, Martin WJ 2nd. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989; 140 (5): 1204-1209.
5. Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest 2000; 118 (3): 704-711.
6. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002; 34 (8): 1098-1107.
7. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984; 100 (5): 663-671.
8. Gerrard JG. Pneumocystis carinii pneumonia in HIV-negative immunocompromised adults. Med J Aust 1995; 162 (2): 233-235.
9. Radisic M, Lattes R, Chapman JF, et al. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study. Transpl Infect Dis 2003; 5 (2): 84-93.
10. Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 1988; 334 (6182): 519-522.
11. Frenkel JK. Pneumocystis pneumonia, an immunodeficiency-dependent disease (IDD): a critical historical overview. J Eukaryot Microbiol 1999; 46 (5): 89S-92S.
12. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004; 350 (24): 2487-2498.
13. Pifer LL, Hughes WT, Stagno S, Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics 1978; 61 (1): 35-41.
14. Kovacs JA, Masur H. Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA 2009; 301 (24): 2578-2585.
15. Wakefield AE, Lindley AR, Ambrose HE, Denis CM, Miller RF. Limited asymptomatic carriage of Pneumocystis jiroveci in human immunodeficiency virus-infected patients. J Infect Dis 2003; 187 (6): 901-908.
16. Cushion MT, Beck JM. Summary of Pneumocystis research presented at the 7th International Workshop on Opportunistic Protists. J Eukaryot Microbiol 2001; 48 (Suppl): 101S-105S.
17. Rabodonirina M, Vanhems P, Couray-Targe S, et al. Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV-infected patients. Emerg Infect Dis 2004; 10 (10): 1766-1773.
18. Morris A, Beard CB, Huang L. Update on the epidemiology and transmission of Pneumocystis carinii. Microbes Infect 2002; 4 (1): 95-103.
19. Bartlett MS, Lee CH, Lu JJ, et al. Pneumocystis carinii detected in air. J Eukaryot Microbiol 1994; 41 (5): 75S.
20. Olsson M, Sukura A, Lindberg LA, Linder E. Detection of Pneumocystis carinii DNA in filtration of air. Scand J Infect Dis 1996; 28 (3): 279-282.
21. Wakefield AE. DNA sequences identical to Pneumocystis carinii f. sp. carinii and Pneumocystis carinii f. sp. hominis in samples of air spora. J Clin Microbiol 1996; 34 (7): 1754-1759.
22. Lundgren B, Elvin K, Rothman LP, Ljungström I, Lidman C, Lundgren JD. Transmission of Pneumocystis carinii from patients to hospital staff. Thorax 1997; 52 (5): 422-424.
23. Morris A, Wei K, Afshar K, Huang L. Epidemiology and clinical significance of Pneumocystis colonization. J Infect Dis 2008; 197 (1): 10-17.
24. Miller RF, Ambrose HE, Wakefield AE. Pneumocystis carinii f. sp. hominis DNA in immunocompetent health care workers in contact with patients with P. carinii pneumonia. J Clin Microbiol 2001; 39 (11): 3877-3882.
25. Vargas SL, Ponce CA, Gigliotti F, et al. Transmission of Pneumocystis carinii DNA from a patient with P. carinii pneumonia to immunocompetent contact health care workers. J Clin Microbiol 2000; 38 (4): 1536-1538.
26. Hughes WT. Natural mode of acquisition for de novo infection with Pneumocystis carinii. J Infect Dis 1982; 145 (6): 842-848.
27. Manoloff ES, Francioli P, Taffé P, Van Melle G, Bille J, Hauser PM. Risk for Pneumocystis carinii transmission among patients with pneumonia: a molecular epidemiology study. Emerg Infect Dis 2003; 9 (1): 132-134.
28. Yazaki H, Goto N, Uchida K, Kobayashi T, Gatanaga H, Oka S. Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients: P. jiroveci is contagious to the susceptible host. Transplantation 2009; 88 (3): 380-385.
29. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996; 71 (1): 5-13.
30. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004; 17 (4): 770-782.
31. Oz HS, Hughes WT. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J Infect Dis 1997; 175 (4): 901-904.
32. Eitner F, Hauser IA, Rettkowski O, et al. Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. Nephrol Dial Transplant 2011; 26 (6): 2013-2017.
33. Lufft V, Kliem V, Behrend M, Pichlmayr R, Koch KM, Brunkhorst R. Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. Transplantation 1996; 62 (3): 421-423.
34. Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC. Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation 2009; 88 (1): 135-141.
35. Arend SM, Westendorp RF, Kroon FP, et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis 1996; 22 (6): 920-925.
36. Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 2001; 33 (8): 1397-1405.
37. Schmoldt S, Schuhegger R, Wendler T, et al. Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J Clin Microbiol 2008; 46 (3): 966-971.
38. de Boer MG, Bruijnesteijn van Coppenraet LE, Gaasbeek A, et al. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source? Clin Infect Dis 2007; 44 (9): 1143-1149.
39. Arichi N, Kishikawa H, Mitsui Y, et al. Cluster outbreak of Pneumocystis pneumonia among kidney transplant patients within a single center. Transplant Proc 2009; 41 (1): 170-172.
40. Kales CP, Murren JR, Torres RA, Crocco JA. Early predictors of in-hospital mortality for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Arch Intern Med 1987; 147 (8): 1413-1417.
41. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357 (25): 2601-2614.
42. Tasaka S, Hasegawa N, Kobayashi S, et al. Serum indicators for the diagnosis of Pneumocystis pneumonia. Chest 2007; 131 (4): 1173-1180.
43. DeLorenzo LJ, Huang CT, Maguire GP, Stone DJ. Roentgenographic patterns of Pneumocystis carinii pneumonia in 104 patients with AIDS. Chest 1987; 91 (3): 323-327.
44. Bigby TD. Diagnosis of Pneumocystis carinii pneumonia. How invasive? Chest 1994; 105 (3): 650-652.
45. Thomas CF Jr, Limper AH. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol 2007; 5 (4): 298-308.
46. Kovacs JA, Ng VL, Masur H, et al. Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies. N Engl J Med 1988; 318 (10): 589-593.
47. Azoulay E, Bergeron A, Chevret S, Bele N, Schlemmer B, Menotti J. Polymerase chain reaction for diagnosing Pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest 2009; 135 (3): 655-661.
48. Ribes JA, Limper AH, Espy MJ, Smith TF. PCR detection of Pneumocystis carinii in bronchoalveolar lavage specimens: analysis of sensitivity and specificity. J Clin Microbiol 1997; 35 (4): 830-835.
49. Yasuoka A, Tachikawa N, Shimada K, Kimura S, Oka S. (1->3) beta-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol 1996; 3 (2): 197-199.
50. Schmatz DM, Romancheck MA, Pittarelli LA, et al. Treatment of Pneumocystis carinii pneumonia with 1, 3-beta-glucan synthesis inhibitors. Proc Natl Acad Sci USA 1990; 87 (15): 5950-5954.
51. Watanabe T, Yasuoka A, Tanuma J, et al. Serum (1->3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis 2009; 49 (7): 1128-1131.
52. de Boer MG, Gelinck LB, van Zelst BD, et al. β-D-glucan and S-adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia in HIV-negative patients: a prospective study. J Infect 2011; 62 (1): 93-100.
53. Matsumura Y, Shindo Y, Iinuma Y, et al. Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC Infect Dis 2011; 11: 76.
54. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58 (RR-4): 1-207; quiz CE1-4.
55. Martin SI, Fishman JA; AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4): S227-S233.
56. Briel M, Bucher HC, Boscacci R, Furrer H. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. Cochrane Database Syst Rev 2006; 3: CD006150.
57. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 1998; 113 (5): 1215-1224.
58. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl 3): S1-S155.
59. Magne D, Angoulvant A, Botterel F, et al. Pneumocystosis: a network survey in the Paris area 2003-2008. Eur J Clin Microbiol Infect Dis 2011; 30 (5): 673-675.
60. Godeau B, Coutant-Perronne V, Le Thi Huong D, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 1994; 21 (2): 246-251.
61. Gianella S, Haeberli L, Joos B, et al. Molecular evidence of interhuman transmission in an outbreak of Pneumocystis jirovecii pneumonia among renal transplant recipients. Transpl Infect Dis 2010; 12 (1): 1-10.
62. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Health Care Infection Control Practices Advisory Committee. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings, June 2007. Am J Infect Control 2007; 25 (10 Suppl 2): S65-S164. Available at.
63. Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000; 342 (19): 1416-1429.
64. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR Recomm Rep 1999; 48 (RR-10): 1-66.
65. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV. 7.1 Late infections. Pneumocystis carinii pneumonia. Nephrol Dial Transplant 2002; 17 (Suppl 4): 36-39.
66. Kasiske BL, Zeier MG, Chapman JR, et al.; Kidney Disease: Improving Outcomes. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010; 77 (4): 299-311.
67. Batiuk TD, Bodziak KA, Goldman M. Infectious disease prophylaxis in renal transplant patients: a survey of US transplant centers. Clin Transplant 2002; 16 (1): 1-8.
68. Mussini C, Pezzotti P, Antinori A, et al.; Changes in Opportunistic Prophylaxis (CIOP) Study Group. Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group. Clin Infect Dis 2003; 36 (5): 645-651.